|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCDH7 |
Gene summary for PCDH7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCDH7 | Gene ID | 5099 |
| Gene name | protocadherin 7 | |
| Gene Alias | BH-Pcdh | |
| Cytomap | 4p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | O60245 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5099 | PCDH7 | CA_HPV_1 | Human | Cervix | CC | 3.22e-11 | -3.68e-01 | 0.0264 |
| 5099 | PCDH7 | CA_HPV_3 | Human | Cervix | CC | 2.37e-03 | -4.27e-02 | 0.0414 |
| 5099 | PCDH7 | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 9.69e-06 | -2.91e-01 | 0.0116 |
| 5099 | PCDH7 | N_HPV_1 | Human | Cervix | N_HPV | 1.91e-05 | -3.07e-01 | 0.0079 |
| 5099 | PCDH7 | CCI_1 | Human | Cervix | CC | 8.22e-07 | 1.26e+00 | 0.528 |
| 5099 | PCDH7 | CCI_2 | Human | Cervix | CC | 4.51e-03 | -3.85e-01 | 0.5249 |
| 5099 | PCDH7 | Tumor | Human | Cervix | CC | 1.81e-03 | -2.34e-01 | 0.1241 |
| 5099 | PCDH7 | sample3 | Human | Cervix | CC | 8.46e-03 | -1.65e-01 | 0.1387 |
| 5099 | PCDH7 | L1 | Human | Cervix | CC | 4.78e-09 | -3.85e-01 | 0.0802 |
| 5099 | PCDH7 | T3 | Human | Cervix | CC | 9.20e-03 | -1.81e-01 | 0.1389 |
| 5099 | PCDH7 | AEH-subject1 | Human | Endometrium | AEH | 3.74e-13 | 5.13e-01 | -0.3059 |
| 5099 | PCDH7 | AEH-subject2 | Human | Endometrium | AEH | 1.61e-25 | 7.34e-01 | -0.2525 |
| 5099 | PCDH7 | AEH-subject5 | Human | Endometrium | AEH | 3.95e-04 | 3.86e-01 | -0.2953 |
| 5099 | PCDH7 | EEC-subject1 | Human | Endometrium | EEC | 1.99e-10 | 4.59e-01 | -0.2682 |
| 5099 | PCDH7 | EEC-subject2 | Human | Endometrium | EEC | 1.87e-24 | 7.11e-01 | -0.2607 |
| 5099 | PCDH7 | EEC-subject3 | Human | Endometrium | EEC | 1.17e-16 | 3.56e-01 | -0.2525 |
| 5099 | PCDH7 | EEC-subject4 | Human | Endometrium | EEC | 1.66e-02 | 2.21e-01 | -0.2571 |
| 5099 | PCDH7 | EEC-subject5 | Human | Endometrium | EEC | 1.00e-02 | 2.55e-01 | -0.249 |
| 5099 | PCDH7 | GSM5276934 | Human | Endometrium | EEC | 3.56e-08 | -3.12e-01 | -0.0913 |
| 5099 | PCDH7 | GSM5276935 | Human | Endometrium | EEC | 2.87e-19 | 5.91e-01 | -0.123 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0098742 | Cervix | N_HPV | cell-cell adhesion via plasma-membrane adhesion molecules | 17/534 | 273/18723 | 2.26e-03 | 2.11e-02 | 17 |
| GO:00987421 | Skin | SCCIS | cell-cell adhesion via plasma-membrane adhesion molecules | 26/919 | 273/18723 | 9.83e-04 | 1.23e-02 | 26 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCDH7 | deletion | Frame_Shift_Del | c.2764delN | p.Phe923LeufsTer137 | p.F923Lfs*137 | O60245 | protein_coding | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |||
| PCDH7 | deletion | Frame_Shift_Del | novel | c.2803delN | p.Lys936ArgfsTer124 | p.K936Rfs*124 | O60245 | protein_coding | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | ||
| PCDH7 | insertion | Frame_Shift_Ins | novel | c.2682_2683insCTAGCTC | p.Tyr895SerfsTer4 | p.Y895Sfs*4 | protein_coding | TCGA-BG-A0MQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| PCDH7 | SNV | Missense_Mutation | c.1866N>A | p.Ser622Arg | p.S622R | O60245 | protein_coding | deleterious(0.01) | possibly_damaging(0.642) | TCGA-BC-A217-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PCDH7 | SNV | Missense_Mutation | c.2361N>A | p.Asn787Lys | p.N787K | O60245 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BC-A217-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PCDH7 | SNV | Missense_Mutation | c.2770N>T | p.Pro924Leu | p.P924L | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-DD-A11A-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| PCDH7 | SNV | Missense_Mutation | c.1866N>A | p.Ser622Arg | p.S622R | O60245 | protein_coding | deleterious(0.01) | possibly_damaging(0.642) | TCGA-DD-A1EE-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| PCDH7 | SNV | Missense_Mutation | novel | c.3175A>T | p.Met1059Leu | p.M1059L | O60245 | protein_coding | tolerated(0.66) | benign(0) | TCGA-DD-AACX-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| PCDH7 | SNV | Missense_Mutation | novel | c.951N>T | p.Leu317Phe | p.L317F | O60245 | protein_coding | deleterious(0.01) | probably_damaging(0.961) | TCGA-DD-AAD5-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| PCDH7 | SNV | Missense_Mutation | novel | c.140T>A | p.Cys48Ser | p.C48S | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.996) | TCGA-DD-AADG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |